Orthofix Medical trades as part of the medical devices industry and is part of the healthcare sector. The company CEO is Bradley R. Mason. Orthofix International NV is a medical device company. It focuses on providing reconstructive and regenerative orthopedic and spine solutions to physicians.
Previous Intraday Performance:
The OFIX shares had a previous change of -0.05% which opened at 55.70 and closed at 55.63. It moved to an intraday high of 56.38 and a low of 55.29.
Over the last five trading days, OFIX shares returned 1.16% and in the past 30 trading days it returned 5.14%. Over three months, it changed -2.01%. In one year it has changed -6.49% and within that year its 52-week high was 74.44 and its 52-week low was 47.79. OFIX stock is 16.40% above its 52 Week Low.
Our calculations result in a 200 day moving average of 56.47 and a 50 day moving average of 56.06. Right now, OFIX stock is trading -1.49% below its 200 day moving average and may be a great opportunity to buy, but should check other technical indicators to confirm a buy signal.
The company has a market cap of $1.1b with 19.1m shares outstanding and a float of 17.2m shares. Trading volume was 74,351 shares and has experienced an average volume of 132,767 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Orthofix Medical was 1.93 which ended on 31st of December 2018, which according to the previous close, that is a PE of 78.35. Based on 2 analyst estimates, the consensus EPS for the next quarter is 0.47. The trailing twelve month EPS is 1.93, which comes to a trailing twelve month PE of 28.82.
Below was the last reported quarterly earnings per share:
Base on our calculations, the intrinsic value per share is 72.94, which means it might be undervalued and has a margin of safety of 23.73%
The next earnings report will be: 03-27-2019
The long-term trend of the EPS is a vital number as it helps understand the future potential of Orthofix Medical; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been 2.10% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 139.80% of institutional ownership.
I calculated the beta to be 0.39
Based on last reported financials, the company’s return on equity is 4.46%, return on assets is 3.23%, profit margin is 3.05%, price-to-sales is 2.34 and price-to-book is 3.16.
Company Score Card:
Results are out of six:
3 : Growth Expectations Result
6 : Financial Safety Result
4 : Past Performance Result
2 : Valuation Result
0 : Dividend Safety Result
3 : Overall Result